After a slow first quarter, biotech IPOs may finally start to come into vogue in the coming months as a series of companies announced plans to go public.
Brain cancer specialist Tocagen is to become the latest biotech to test the waters with an IPO this year, after mixed success for recent market launches.
After two giddy years of continuous growth, biotech got a rude awakening in late 2015, but many remain confident in the sector's growth potential, writes Andrew McConaghie.
